Table 2 The pattern of TTX in patients receiving combination IFN-α and RBVNo thyroid nuclear or ultrasonic imaging was available for all thyrotoxic cases
Subjects | 1 | 2 | 3 |
|---|---|---|---|
Gender | F | F | M |
Age | 26 | 35 | 36 |
HCV Genotype | 1a | 3a | 1g |
Regimen duration (weeks) | 48 | 24 | 24 |
Adverse reactions | Myalgia, lethargy, emotional lability | None | Insomnia, rash |
Baseline ALT | 184 | 142 | 104 |
ALT at time of thyroid disease | 33 | 28 | 17 |
Duration of therapy prior to thyroid disease (weeks) | 16 | 8 | 32 |
Symptoms of thyroid disease | Anxiety and depression | Non-specific | Non-specific |
Signs | No goitre | No goitre | No goitre |
Peak fT4 (pmol/L) | 56.7 | 57.0 | 27.0 |
Peak fT3 (pmol/L) | 15.1 | 15.3 | 12.8 |
Thyroid autoantibody status | • Anti-Tg <1 • Anti-TPO 1:409,600 • TSI <1 | • Anti-Tg <1 • Anti-TPO 1:409,600 • TSI <1 | • Anti-Tg <1 • Anti-TPO <1:100 • TSI <1 |
Thyroid outcomes | Hypothyroidism on replacement therapy | Hypothyroidism on replacement therapy | Thyroid condition resolved with IFN-α dose reduction |
Hepatic outcomes | PCR negative | PCR negative | PCR negative |